Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2455427-91-3
2. Azd-0780
3. 1-[6-[[(1s,3s)-3-[[5-(difluoromethoxy)pyrimidin-2-yl]amino]cyclopentyl]amino]pyridin-3-yl]pyridin-2-one
4. Schembl22241911
5. Gtpl13419
6. Azd0780
7. Nchuwrlotsaffn-kbpbesrzsa-n
8. Bdbm537931
9. Ex-a6975
10. Us11248001, Example 458b
11. Example 458b [us11248001b2]
12. Da-76642
13. Ms-27171
14. Hy-148673
15. Cs-0636856
Molecular Weight | 414.4 g/mol |
---|---|
Molecular Formula | C20H20F2N6O2 |
XLogP3 | 3.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 7 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 92.3 |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 641 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing in a range of cardiovascular disease.
Lead Product(s): YS2302018,AZD0780
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: YS2302018
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: AstraZeneca
Deal Size: $2,020.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement October 07, 2024
Lead Product(s) : YS2302018,AZD0780
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : AstraZeneca
Deal Size : $2,020.0 million
Deal Type : Licensing Agreement
AstraZeneca Puts $2B on The Line for Preclinical Heart Disease Drug
Details : AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing in a range of cardiovascular disease.
Brand Name : YS2302018
Molecule Type : Small molecule
Upfront Cash : $100.0 million
October 07, 2024
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?